Bellerophon Therapeutics LLC (NASDAQ: BLPH)is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. Its mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need. For more information, visit the company’s website at www.bellerophon.com.
Bellerophon Therapeutics (BLPH) Presents at Rodman & Renshaw Conference
Previous Article
Next Article
Search Articles
Latest Articles
- MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present Corporate Update at Emerging Growth Conference on Aug. 20
- MissionIRNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Announces Juve Stabia Coppa Italia Opener Against Serie A’s US Lecce
- MissionIRNewsBreaks – FAVO Capital (OTC: FAVO) Acquires $190 Million Mixed-Use Property 1818 Park in All-Stock Deal
- MissionIRNewsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Sees 504% Boat Sales Surge, Slashes Debt Following Nautical Ventures Acquisition
- MissionIRNewsBreaks – Massimo Group (NASDAQ: MAMO) Expands Retail Footprint into Oregon and Arkansas